Elevai Labs Inc (ELAB) 銘柄情報

ELAB.............................https://stockcharts.com/h-sc/ui?s=ELAB&p=W&b=5&g=0&id=p86431144783

.14 now see you at .23 resistance for the dump

EL-22 alongside GLP-1 receptor agonists, marking a significant advancement in obesity treatment.
The newly filed patent applications support the development of EL-22, an engineered probiotic expressing myostatin, designed to revolutionize obesity care by preserving muscle mass while reducing fat mass. EL-22 has successfully completed a Phase 1 clinical trial in South Korea, demonstrating safety and tolerability in healthy volunteers. Elevai now plans to assess the efficacy of EL-22 in combination with leading weight-loss therapies to address muscle wasting—a common side effect of GLP-1 medications—while promoting fat loss.

“While GLP-1 medications such as Ozempic®, Wegovy®, and Mounjaro® dominate the obesity market, a critical gap remains in preserving lean muscle mass during weight loss,” said Deniel Mero, Co-Founder of Elevai Biosciences. “Muscle mass is vital for metabolism, strength, and overall mobility, and our patented EL-22 technology aims to address this unmet need with a first-in-class approach leveraging myostatin inhibition and oral delivery.”

The first patent application, titled “Fusion Protein of MYO-2 for Use in Treating Muscle Loss in Obese Patients” (Patent Application Serial No. 18/895,501), focuses on EL-22 as a monotherapy for treating muscle loss in obese patients. The second patent application, “Combination Therapy of a Fusion Protein of MYO-2 with a GLP-1 Receptor Agonist for Treating Muscle Loss in Obese Patients” (Patent Application Serial No. 18/895,519), covers the use of EL-22 in combination with GLP-1 receptor agonists, enhancing the benefits of current weight-loss drugs by preserving muscle mass.

These patent applications strengthen Elevai's intellectual property portfolio as the Company advances its mission to transform the standard of care for obesity treatment, with the potential to offer a differentiated therapy that preserves muscle loss, a critical component for patient health and quality of life. Elevai Biosciences’ patent portfolio now includes 4 patent applications and 5 issued patents that provide adequate protection in focus markets, including the USA, Japan, China and Korea.

Licensed Product / Nation Patent Application Serial No. Title:
EL-32 USA 18/627,462 Pharmaceutical composition for alleviation, treatment, and prevention of sarcopenia containing microorganism transformed with cell surface display vector operably linked with gene encoding myostatin and activin A proteins as active ingredient
EL-32 Korea 10-2022-0136606 A pharmaceutical composition for alleviation, treatment and prevention of sarcopenia containing a microorganism transformed with a vector expressing myostatin and activin A on the cell surface as an active ingredient
EL-22 USA 18/895,501 Fusion Protein of Myo-2 for Use in Treating Muscle Loss in Obese Patients
EL-22 USA 18/895,519 Combination Therapy of a Fusion Protein of Myo-2 with a GLP-1 Receptor Agonist for Use in Treating Muscle Loss in Obese Patients

Patent No. Registration No. Title:
EL-22 Korea 10-0857861-0000 Surface Expression Vector for Fusion Protein of Myo-2 Peptide Multimer and Myostatin, and Microorganism Transformed by Thereof
EL-22 Korea 10-0872042-0000 Cell Surface Expression Vector of Myostatin and Microorganisms Transformed Thereby
EL-22 USA 8470551 Surface Expression Vector for Fusion Protein of Myo-2 Peptide Multimer and Myostatin, and Microorganism Transformed by Thereof
EL-22 Japan 5634867 Surface Expression Vector for Fusion Protein of Myo-2 Peptide Multimer and Myostatin, and Microorganism Transformed by Thereof
EL-22 China ZL200780101116.2 Surface Expression Vector for Fusion Protein of Myo-2 Peptide Multimer and Myostatin, and Microorganism Transformed by Thereof

Almost hit .15 + 60%

Reverse split in the foreseeable future?

$elab PRE 14c dropped an hour ago https://t.co/rPqjtUmyrE— Joshua Smith (@hokieman04) September 28, 2024

elab........................
https://stockcharts.com/h-sc/ui?s=elab&p=W&b=5&g=0&id=p86431144783

ELAB...................................https://stockcharts.com/h-sc/ui?s=ELAB&p=W&b=5&g=0&id=p86431144783

Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Encouraging Data Results Indicating Potential for Hair Restoration Using Proprietary Exosome Technology

ELAB...34...Moving on Patent News...🥳

georgie18

Member Level
Re: georgie18 post# 655074

Monday, August 26, 2024 10:11:31 AM

Post#
655191
of 655453
ELAB...33s clearing here on News...🥳

georgie18

Member Level
Re: georgie18 post# 24

Friday, August 23, 2024 3:52:32 PM

Post#
25
of 28
ELAB...317...coming back here...🥳Alerted at 324...added the 25 range dip...

ELAB...33s clearing here on News...🥳

georgie18

Member Level
Re: georgie18 post# 24

Friday, August 23, 2024 3:52:32 PM

Post#
25
of 28
ELAB...317...coming back here...🥳Alerted at 324...added the 25 range dip...

Catch some .40s then dump again?

https://finviz.com/quote.ashx?t=ELAB&ty=c&ta=1&p=d

ELAB...................................................https://stockcharts.com/h-sc/ui?s=ELAB&p=W&b=5&g=0&id=p86431144783

ELAB...317...coming back here...🥳Alerted at 324...added the 25 range dip...

ELAB...324... https://schrts.co/khJaWBxK ...Oversold Chart...🥳

Skinning some shorts however won’t last long

https://www.zacks.com/stock/news/2300964/the-zacks-analyst-blog-highlights-danaher-morgan-stanley-pfizer-elite-pharmaceuticals-and-oil-dri
https://www.zacks.com/stock/news/2300922/zacks-initiates-coverage-of-elite-pharmaceuticals-with-outperform-recommendation

Elevai Labs Expands with Launch of Elevai Biosciences and Elevai Skincare Subsidiaries, Advancing the Future of Aesthetic Medicines and Exosome Skincare

This stock just can't stay up....someone give this pos some Viagra!

https://stocktwits.com/3227blake/message/562545429

$ELAB bottom chart 1.8M float no dilution and 6.6 months of cash with 22.07% 13D out today, only 20k short shares left pic.twitter.com/EFsfxgkXqv— STOCKS Gambino (@StocksGambino) February 21, 2024

ELAB: Had skin care Patent, 1-wk. ago; maybe now an outright cure for all CANCERS??? (Joking)

Goodmorning

and then randomly 4am .70-1.65 no news, just some more games

if it breaks 1.65 it could go

otherwise 1 & done pos pump 2.0

ELAB $1.64 just a quick premarket flip they can do all the dilution they want after 7am..lol

NO THX https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173636262

EVEN THOUGH i MADE A SMALL TRADE AND SOLD 1.49

ELAB IS STILL A POS IMO

Almost hit 1.30 zones 1.39- 1.60 further up

Dilution? Total mess.

Dilution? Total mess.

$ELAB MORE NEWS Reports Strong Preliminary Unaudited Financial Performance for Fiscal Year 2023, Highlighting Significant Revenue Growth and Expanding Global Reach

https://newsfilter.io/articles/elevai-labs-inc-reports-strong-preliminary-unaudited-financial-performance-for-fiscal-year-2023-high-6ea3644ed452e4ef1c28f33c0f9f63c8

Yes, very strange
Morning news Today the/ Shorts piled in:((

ELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology

ELEVAI Labs to commercialize use of proprietary technology designed to produce high-quality, cGMP grade mesenchymal stromal cells at lower-cost

NEWPORT BEACH, Calif., Jan. 16, 2024 -- InvestorsHub NewsWire -- Elevai Labs, Inc. (Nasdaq: ELAB) a medical aesthetic company specializing in physician-dispensed skincare is pleased to announce it has signed an exclusive, worldwide manufacturing and processing technology licensing agreement with INmune Bio, Inc., [Nasdaq: INMB]. The licensing agreement grants Elevai a license to use INmune Bio's proprietary "EMx" technology, developed by INmune Bio, Inc., CMO, Mark Lowdell, PhD, that enables Elevai to manufacture current Good Manufacturing Practice ("cGMP") grade, human umbilical cord-derived mesenchymal stromal cells (hucMSCs) at a lower cost to Elevai than purchasing hucMSCs outright. Manufactured hucMSCs can be incorporated into certain licensed topical cosmetic products sold in the medical aesthetics skincare market.

Elevai believes incorporating the "EMx" technology into its operations is a step towards the company's goal of achieving vertical manufacturing integration, while also expanding long-term production capabilities and lowering overall costs. Ultimately, Elevai believes controlling its processes through its product pipeline with what it believes to be efficient technologies like "EMx" will allow greater stem cell consistency, purity, and propel Elevai's branded cosmetic products further to maintain the company's position as an industry innovator in the medical aesthetics skincare marke

SEC gives no shits

this is exactly why we 100% need Crypto, every share will be tracked every step of the way long or short

now its all a mystery, with offshore BS

cryptonize the stock market to STOP this naked shorting BS

a long time ago one senator wanted to add a serial # like a vin# to every share so companies, and shareholders could account for every share

well crypto enables exactly that, and is fully transparent on the blockchain

#THINKABOUTIT

Classic chat pump & dump naked short
To 1.00;((

definitely not a good way to start a business.

LOOKS LIKE NEWS PUMP TO DUMP SHARES IMO

https://elevaiskincare.com/
FLUFFY PUFFY SKIN ..NEWS

OVER EXTENDED POP

GAP & TRAP

BUT -11.11% IS DOWN RIGHT DISGUSTING AFTER BEING UP UP OVER 100% 4.38 HIGH

$ELAB

this is looking very interesting. The rise is due to the acquisition. Why the fall?

Hello world:)

Recent ipo